<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32414108</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>13</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Enhanced Clearance of Neurotoxic Misfolded Proteins by the Natural Compound Berberine and Its Derivatives.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3443</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21103443</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Accumulation of misfolded proteins is a common hallmark of several neurodegenerative disorders (NDs) which results from a failure or an impairment of the protein quality control (PQC) system. The PQC system is composed by chaperones and the degradative systems (proteasome and autophagy). Mutant proteins that misfold are potentially neurotoxic, thus strategies aimed at preventing their aggregation or at enhancing their clearance are emerging as interesting therapeutic targets for NDs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We tested the natural alkaloid berberine (BBR) and some derivatives for their capability to enhance misfolded protein clearance in cell models of NDs, evaluating which degradative pathway mediates their action.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that both BBR and its semisynthetic derivatives promote degradation of mutant androgen receptor (ARpolyQ) causative of spinal and bulbar muscular atrophy, acting mainly via proteasome and preventing ARpolyQ aggregation. Overlapping effects were observed on other misfolded proteins causative of amyotrophic lateral sclerosis, frontotemporal-lobar degeneration or Huntington disease, but with selective and specific action against each different mutant protein.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">BBR and its analogues induce the clearance of misfolded proteins responsible for NDs, representing potential therapeutic tools to counteract these fatal disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rusmini</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Dipartimento di Eccellenza 2018-2022, Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cristofani</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Dipartimento di Eccellenza 2018-2022, Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tedesco</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Dipartimento di Eccellenza 2018-2022, Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Dipartimento di Eccellenza 2018-2022, Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messi</LastName><ForeName>Elio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Dipartimento di Eccellenza 2018-2022, Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccolella</LastName><ForeName>Margherita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Dipartimento di Eccellenza 2018-2022, Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casarotto</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Dipartimento di Eccellenza 2018-2022, Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chierichetti</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Dipartimento di Eccellenza 2018-2022, Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cicardi</LastName><ForeName>Maria Elena</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Dipartimento di Eccellenza 2018-2022, Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, 20133 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jefferson Weinberg ALS Center, Vickie and Jack Farber Institute for Neuroscience, Sidney Kimmel Medical College, Department of Neuroscience, Thomas Jefferson University, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galbiati</LastName><ForeName>Mariarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Dipartimento di Eccellenza 2018-2022, Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geroni</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Naxospharma srl, 20026 Novate Milanese, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Naxospharma srl, 20026 Novate Milanese, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crippa</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Dipartimento di Eccellenza 2018-2022, Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poletti</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Dipartimento di Eccellenza 2018-2022, Centro di Eccellenza sulle Malattie Neurodegenerative, Universit&#xe0; degli Studi di Milano, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GGP14039</GrantID><Agency>Fondazione Telethon</Agency><Country/></Grant><Grant><GrantID>GGP19128</GrantID><Agency>Fondazione Telethon</Agency><Country/></Grant><Grant><GrantID>2018 Grant</GrantID><Agency>Kennedy's disease association</Agency><Country/></Grant><Grant><GrantID>2014-0686</GrantID><Agency>Fondazione Cariplo</Agency><Country/></Grant><Grant><GrantID>2017_0747</GrantID><Agency>Fondazione Cariplo</Agency><Country/></Grant><Grant><GrantID>ALS_HSPB8</GrantID><Agency>Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica</Agency><Country/></Grant><Grant><GrantID>ALS_Granulopathy</GrantID><Agency>Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica</Agency><Country/></Grant><Grant><GrantID>MLOpathy</GrantID><Agency>Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica</Agency><Country/></Grant><Grant><GrantID>Target-RAN</GrantID><Agency>Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica</Agency><Country/></Grant><Grant><GrantID>16406</GrantID><Agency>AFM-T&#xe9;l&#xe9;thon</Agency><Country/></Grant><Grant><GrantID>Piano di sviluppo UNIMI - linea B</GrantID><Agency>Universit&#xe0; degli Studi di Milano</Agency><Country/></Grant><Grant><GrantID>Bando Straordinario per Progetti Interdipartimentali (Bando SEED 2019: #TDP-43-iPSC</GrantID><Agency>Universit&#xe0; degli Studi di Milano</Agency><Country/></Grant><Grant><GrantID>PRIN 2015LFPNMN</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>2017F2A2C5</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>Fondo per il Finanziamento delle Attivit&#xe0; Base di Ricerca (FFABR)</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>Co_ALS</GrantID><Agency>Agenzia Italiana del Farmaco, Ministero della Salute</Agency><Country/></Grant><Grant><GrantID>GR-2011-02347198</GrantID><Agency>Ministero della Salute</Agency><Country/></Grant><Grant><GrantID>TRANS_ALS, project nr. 2015-0023</GrantID><Agency>Fondazione Regionale per la Ricerca Biomedica (FRRB) (Regione Lombardia</Agency><Country/></Grant><Grant><GrantID>01ED1601A, CureALS</GrantID><Agency>EU Joint Programme - Neurodegenerative Disease Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001688">Biological Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0I8Y3P32UF</RegistryNumber><NameOfSubstance UI="D001599">Berberine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001599" MajorTopicYN="N">Berberine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001688" MajorTopicYN="N">Biological Products</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020258" MajorTopicYN="N">Neurotoxicity Syndromes</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057165" MajorTopicYN="N">Proteostasis Deficiencies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">berberine</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">misfolding</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">proteasome</Keyword><Keyword MajorTopicYN="N">protein aggregation</Keyword><Keyword MajorTopicYN="N">spinal and bulbar muscular atrophy</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32414108</ArticleId><ArticleId IdType="pmc">PMC7279252</ArticleId><ArticleId IdType="doi">10.3390/ijms21103443</ArticleId><ArticleId IdType="pii">ijms21103443</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Skowyra M.L., Schlesinger P.H., Naismith T.V., Hanson P.I. Triggered recruitment of ESCRT machinery promotes endolysosomal repair. Science. 2018;360:eaar5078. doi: 10.1126/science.aar5078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aar5078</ArticleId><ArticleId IdType="pmc">PMC6195421</ArticleId><ArticleId IdType="pubmed">29622626</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B., Retzlaff M., Roos T., Frydman J. Cellular Strategies of Protein Quality Control. Cold Spring Harb. Perspect. Biol. 2011;3:a004374. doi: 10.1101/cshperspect.a004374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a004374</ArticleId><ArticleId IdType="pmc">PMC3140689</ArticleId><ArticleId IdType="pubmed">21746797</ArticleId></ArticleIdList></Reference><Reference><Citation>Korolchuk V.I., Menzies F.M., Rubinsztein D.C. A novel link between autophagy and the ubiquitin-proteasome system. Autophagy. 2009;5:862&#x2013;863. doi: 10.4161/auto.8840.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.8840</ArticleId><ArticleId IdType="pubmed">19458478</ArticleId></ArticleIdList></Reference><Reference><Citation>Saelices L., Johnson L.M., Liang W.Y., Sawaya M.R., Cascio D., Ruchala P., Whitelegge J., Jiang L., Riek R., Eisenberg D.S. Uncovering the Mechanism of Aggregation of Human Transthyretin. J. Biol. Chem. 2015;290:28932&#x2013;28943. doi: 10.1074/jbc.M115.659912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.659912</ArticleId><ArticleId IdType="pmc">PMC4661406</ArticleId><ArticleId IdType="pubmed">26459562</ArticleId></ArticleIdList></Reference><Reference><Citation>Bence N.F., Sampat R.M., Kopito R.R. Impairment of the Ubiquitin-Proteasome System by Protein Aggregation. Science. 2001;292:1552&#x2013;1555. doi: 10.1126/science.292.5521.1552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.292.5521.1552</ArticleId><ArticleId IdType="pubmed">11375494</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Mucke L. Alzheimer Mechanisms and Therapeutic Strategies. Cell. 2012;148:1204&#x2013;1222. doi: 10.1016/j.cell.2012.02.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.02.040</ArticleId><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross C.A., Poirier M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004;10:S10&#x2013;S17. doi: 10.1038/nm1066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1066</ArticleId><ArticleId IdType="pubmed">15272267</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox D., Raeburn C., Sui X., Hatters D.M. Protein aggregation in cell biology: An aggregomics perspective of health and disease. Semin. Cell Dev. Biol. 2020;99:40&#x2013;54. doi: 10.1016/j.semcdb.2018.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2018.05.003</ArticleId><ArticleId IdType="pubmed">29753879</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo A.M., Bergamini E., Brunk U.T., Dr&#xf6;ge W., Ffrench M., Terman A. Autophagy and aging: The importance of maintaining &#x201c;clean&#x201d; cells. Autophagy. 2005;1:131&#x2013;140. doi: 10.4161/auto.1.3.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.1.3.2017</ArticleId><ArticleId IdType="pubmed">16874025</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Sato Y., Nixon R.A. Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer&#x2019;s-like axonal dystrophy. J. Neurosci. 2011;31:7817&#x2013;7830. doi: 10.1523/JNEUROSCI.6412-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6412-10.2011</ArticleId><ArticleId IdType="pmc">PMC3351137</ArticleId><ArticleId IdType="pubmed">21613495</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan H.-C., Ho L.-I., Chi C.-S., Chen S.-J., Peng G.-S., Chan T.-M., Lin S.-Z., Harn H.-J. Polyglutamine (PolyQ) Diseases: Genetics to Treatments. Cell Transplant. 2014;23:441&#x2013;458. doi: 10.3727/096368914X678454.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096368914X678454</ArticleId><ArticleId IdType="pubmed">24816443</ArticleId></ArticleIdList></Reference><Reference><Citation>Adegbuyiro A., Sedighi F., Pilkington A.W., Groover S., Legleiter J. Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease. Biochemistry. 2017;56:1199&#x2013;1217. doi: 10.1021/acs.biochem.6b00936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.6b00936</ArticleId><ArticleId IdType="pmc">PMC5727916</ArticleId><ArticleId IdType="pubmed">28170216</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischbeck K.H., Lieberman A., Bailey C.K., Abel A., Merry D.E. Androgen receptor mutation in Kennedy&#x2019;s disease. Philos. Trans. R. Soc. B Biol. Sci. 1999;354:1075&#x2013;1078. doi: 10.1098/rstb.1999.0461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.1999.0461</ArticleId><ArticleId IdType="pmc">PMC1692603</ArticleId><ArticleId IdType="pubmed">10434308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy W.R., Alter M., Sung J.H. Progressive proximal spinal and bulbar muscular atrophy of late onset: A sex-linked recessive trait. Neurology. 1968;18:671. doi: 10.1212/WNL.18.7.671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.18.7.671</ArticleId><ArticleId IdType="pubmed">4233749</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G., Bede P., Marchand-Pauvert V., Pradat P.-F. Biomarkers of Spinal and Bulbar Muscle Atrophy (SBMA): A Comprehensive Review. Front. Neurol. 2018;9:844. doi: 10.3389/fneur.2018.00844.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00844</ArticleId><ArticleId IdType="pmc">PMC6191472</ArticleId><ArticleId IdType="pubmed">30364135</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka F., Doyu M., Ito Y., Matsumoto M., Mitsuma T., Abe K., Aoki M., Itoyama Y., Fischbeck K.H., Sobue G. Founder effect in spinal and bulbar muscular atrophy (SBMA) Hum. Mol. Genet. 1996;5:1253&#x2013;1257. doi: 10.1093/hmg/5.9.1253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/5.9.1253</ArticleId><ArticleId IdType="pubmed">8872464</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunseich C., Rinaldi C., Fischbeck K.H. Spinal and bulbar muscular atrophy: Pathogenesis and clinical management. Oral Dis. 2013;20:6&#x2013;9. doi: 10.1111/odi.12121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/odi.12121</ArticleId><ArticleId IdType="pmc">PMC4284073</ArticleId><ArticleId IdType="pubmed">23656576</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejager S., Bry-Gauillard H., Bruckert E., Eymard B., Salachas F., LeGuern E., Tardieu S., Chadarevian R., Giral P., Turpin G. A Comprehensive Endocrine Description of Kennedy&#x2019;s Disease Revealing Androgen Insensitivity Linked to CAG Repeat Length. J. Clin. Endocrinol. Metab. 2002;87:3893&#x2013;3901. doi: 10.1210/jcem.87.8.8780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem.87.8.8780</ArticleId><ArticleId IdType="pubmed">12161529</ArticleId></ArticleIdList></Reference><Reference><Citation>Vegeto E., Villa A., Della Torre S., Crippa V., Rusmini P., Cristofani R., Galbiati M., Maggi A., Poletti A. The Role of Sex and Sex Hormones in Neurodegenerative Diseases. Endocr. Rev. 2019;41:273&#x2013;319. doi: 10.1210/endrev/bnz005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endrev/bnz005</ArticleId><ArticleId IdType="pmc">PMC7156855</ArticleId><ArticleId IdType="pubmed">31544208</ArticleId></ArticleIdList></Reference><Reference><Citation>Davey R.A., Grossmann M. Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin. Biochem. Rev. 2016;37:3&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4810760</ArticleId><ArticleId IdType="pubmed">27057074</ArticleId></ArticleIdList></Reference><Reference><Citation>Mhaouty-Kodja S. Role of the androgen receptor in the central nervous system. Mol. Cell. Endocrinol. 2018;465:103&#x2013;112. doi: 10.1016/j.mce.2017.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2017.08.001</ArticleId><ArticleId IdType="pubmed">28826929</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois V., Laurent M.R., Boonen S., Vanderschueren D., Claessens F. Androgens and skeletal muscle: Cellular and molecular action mechanisms underlying the anabolic actions. Cell. Mol. Life Sci. 2011;69:1651&#x2013;1667. doi: 10.1007/s00018-011-0883-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-011-0883-3</ArticleId><ArticleId IdType="pubmed">22101547</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzano R., Sorar&#xf9; G., Grunseich C., Fratta P., Zuccaro E., Pennuto M., Rinaldi C. Beyond motor neurons: Expanding the clinical spectrum in Kennedy&#x2019;s disease. J. Neurol. Neurosurg. Psychiatry. 2018;89:808&#x2013;812. doi: 10.1136/jnnp-2017-316961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316961</ArticleId><ArticleId IdType="pmc">PMC6204939</ArticleId><ArticleId IdType="pubmed">29353237</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti A. The polyglutamine tract of androgen receptor: From functions to dysfunctions in motor neurons. Front. Neuroendocr. 2004;25:1&#x2013;26. doi: 10.1016/j.yfrne.2004.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yfrne.2004.03.001</ArticleId><ArticleId IdType="pubmed">15183036</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccioni F., Simeoni S., Andriola I., Armatura E., Bassanini S., Pozzi P., Poletti A. Polyglutamine tract expansion of the androgen receptor in a motoneuronal model of spinal and bulbar muscular atrophy. Brain Res. Bull. 2001;56:215&#x2013;220. doi: 10.1016/S0361-9230(01)00652-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0361-9230(01)00652-9</ArticleId><ArticleId IdType="pubmed">11719253</ArticleId></ArticleIdList></Reference><Reference><Citation>Simeoni S., Mancini M., Stenoien D.L., Marcelli M., Weigel N.L., Zanisi M., Martini L., Poletti A. Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract. Hum. Mol. Genet. 2000;9:133&#x2013;144. doi: 10.1093/hmg/9.1.133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/9.1.133</ArticleId><ArticleId IdType="pubmed">10587588</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P., Sau D., Crippa V., Palazzolo I., Simonini F., Onesto E., Martini L., Poletti A. Aggregation and proteasome: The case of elongated polyglutamine aggregation in spinal and bulbar muscular atrophy. Neurobiol. Aging. 2007;28:1099&#x2013;1111. doi: 10.1016/j.neurobiolaging.2006.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.05.015</ArticleId><ArticleId IdType="pubmed">16781019</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I., Gliozzi A., Rusmini P., Sau D., Crippa V., Simonini F., Onesto E., Bolzoni E., Poletti A. The role of the polyglutamine tract in androgen receptor. J. Steroid Biochem. Mol. Biol. 2008;108:245&#x2013;253. doi: 10.1016/j.jsbmb.2007.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsbmb.2007.09.016</ArticleId><ArticleId IdType="pubmed">17945479</ArticleId></ArticleIdList></Reference><Reference><Citation>Podvin S., Reardon H., Yin K., Mosier C., Hook V. Multiple clinical features of Huntington&#x2019;s disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration. J. Neurol. 2018;266:551&#x2013;564. doi: 10.1007/s00415-018-8940-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8940-6</ArticleId><ArticleId IdType="pubmed">29956026</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiner A., Dragatsis I., Zeitlin S.O., Goldowitz D. Wild-Type Huntingtin Plays a Role in Brain Development and Neuronal Survival. Mol. Neurobiol. 2003;28:259&#x2013;276. doi: 10.1385/MN:28:3:259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/MN:28:3:259</ArticleId><ArticleId IdType="pubmed">14709789</ArticleId></ArticleIdList></Reference><Reference><Citation>Rui Y.-N., Xu Z., Patel B., Chen Z., Chen N., Tito A., David G., Sun Y., Stimming E.F., Bellen H.J., et al. Huntingtin functions as a scaffold for selective macroautophagy. Nat. Cell Biol. 2015;17:262&#x2013;275. doi: 10.1038/ncb3101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3101</ArticleId><ArticleId IdType="pmc">PMC4344873</ArticleId><ArticleId IdType="pubmed">25686248</ArticleId></ArticleIdList></Reference><Reference><Citation>White J., Anderson E., Zimmerman K., Zheng K.H., Rouhani R., Gunawardena S. Huntingtin differentially regulates the axonal transport of a sub-set of Rab-containing vesicles in vivo. Hum. Mol. Genet. 2015;24:7182&#x2013;7195. doi: 10.1093/hmg/ddv415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv415</ArticleId><ArticleId IdType="pmc">PMC4664163</ArticleId><ArticleId IdType="pubmed">26450517</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte J., Littleton J.T. Relevance to Huntington&#x2019; s Disease Pathology. Curr. Trends Neurol. 2011;5:65&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3237673</ArticleId><ArticleId IdType="pubmed">22180703</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P., Cortese K., Crippa V., Cristofani R., Cicardi M.E., Ferrari V., Vezzoli G., Tedesco B., Meroni M., Messi E., et al. Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration. Autophagy. 2018;15:631&#x2013;651. doi: 10.1080/15548627.2018.1535292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2018.1535292</ArticleId><ArticleId IdType="pmc">PMC6526812</ArticleId><ArticleId IdType="pubmed">30335591</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristofani R., Crippa V., Rusmini P., Cicardi M.E., Meroni M., Licata N.V., Sala G., Giorgetti E., Grunseich C., Galbiati M., et al. Inhibition of retrograde transport modulates misfolded protein accumulation and clearance in motoneuron diseases. Autophagy. 2017;13:1280&#x2013;1303. doi: 10.1080/15548627.2017.1308985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2017.1308985</ArticleId><ArticleId IdType="pmc">PMC5584856</ArticleId><ArticleId IdType="pubmed">28402699</ArticleId></ArticleIdList></Reference><Reference><Citation>Klickovic U., Zampedri L., Sinclair C.D., Wastling S.J., Trimmel K., Howard R.S., Malaspina A., Sharma N., Sidle K., Emira A., et al. Skeletal muscle MRI differentiates SBMA and ALS and correlates with disease severity. Neurology. 2019;93:e895&#x2013;e907. doi: 10.1212/WNL.0000000000008009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008009</ArticleId><ArticleId IdType="pmc">PMC6745729</ArticleId><ArticleId IdType="pubmed">31391248</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S., Goizet C., Soulages A., Vallat J.-M., Le Masson G. Masson Genetics of amyotrophic lateral sclerosis: A review. J. Neurol. Sci. 2019;399:217&#x2013;226. doi: 10.1016/j.jns.2019.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.02.030</ArticleId><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M., Conte A., Zollino M. Clinical and genetic heterogeneity of amyotrophic lateral sclerosis. Clin. Genet. 2013;83:408&#x2013;416. doi: 10.1111/cge.12117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cge.12117</ArticleId><ArticleId IdType="pubmed">23379621</ArticleId></ArticleIdList></Reference><Reference><Citation>Pansarasa O., Bordoni M., Diamanti L., Sproviero D., Gagliardi S., Cereda C. SOD1 in Amyotrophic Lateral Sclerosis: &#x201c;Ambivalent&#x201d; Behavior Connected to the Disease. Int. J. Mol. Sci. 2018;19:1345. doi: 10.3390/ijms19051345.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19051345</ArticleId><ArticleId IdType="pmc">PMC5983710</ArticleId><ArticleId IdType="pubmed">29751510</ArticleId></ArticleIdList></Reference><Reference><Citation>Berning B., Walker A.K. The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD. Front. Mol. Neurosci. 2019;13:335. doi: 10.3389/fnins.2019.00335.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00335</ArticleId><ArticleId IdType="pmc">PMC6470282</ArticleId><ArticleId IdType="pubmed">31031584</ArticleId></ArticleIdList></Reference><Reference><Citation>Winklhofer K.F., Tatzelt J., Haass C. The two faces of protein misfolding: Gain- and loss-of-function in neurodegenerative diseases. EMBO J. 2008;27:336&#x2013;349. doi: 10.1038/sj.emboj.7601930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601930</ArticleId><ArticleId IdType="pmc">PMC2234348</ArticleId><ArticleId IdType="pubmed">18216876</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka K., Matsuda N. Proteostasis and neurodegeneration: The roles of proteasomal degradation and autophagy. Biochim. Biophys. Acta (BBA) Bioenerg. 2014;1843:197&#x2013;204. doi: 10.1016/j.bbamcr.2013.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2013.03.012</ArticleId><ArticleId IdType="pubmed">23523933</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgetti E., Rusmini P., Crippa V., Cristofani R., Boncoraglio A., Cicardi M.E., Galbiati M., Poletti A. Synergic prodegradative activity of Bicalutamide and trehalose on the mutant androgen receptor responsible for spinal and bulbar muscular atrophy. Hum. Mol. Genet. 2014;24:64&#x2013;75. doi: 10.1093/hmg/ddu419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu419</ArticleId><ArticleId IdType="pmc">PMC4262493</ArticleId><ArticleId IdType="pubmed">25122660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting H.-C., Chang C.-Y., Lu K.Y., Chuang H.-M., Tsai S.-F., Huang M.-H., Liu C.-A., Lin S.-Z., Harn H.-J. Targeting Cellular Stress Mechanisms and Metabolic Homeostasis by Chinese Herbal Drugs for Neuroprotection. Molecules. 2018;23:259. doi: 10.3390/molecules23020259.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules23020259</ArticleId><ArticleId IdType="pmc">PMC6017457</ArticleId><ArticleId IdType="pubmed">29382106</ArticleId></ArticleIdList></Reference><Reference><Citation>Rad S.Z.K., Rameshrad M., Hosseinzadeh H. Toxicology effects of Berberis vulgaris (barberry) and its active constituent, berberine: A review. Iran. J. Basic Med. Sci. 2017;20:516&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5478780</ArticleId><ArticleId IdType="pubmed">28656087</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz L.M.G., Lombardi P., Tillhon M., Scovassi A.I. Berberine, an Epiphany Against Cancer. Molecules. 2014;19:12349&#x2013;12367. doi: 10.3390/molecules190812349.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules190812349</ArticleId><ArticleId IdType="pmc">PMC6271598</ArticleId><ArticleId IdType="pubmed">25153862</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou K., Li Z., Zhang Y., Zhang H.-Y., Li B., Zhu W.-L., Shi J., Jia Q., Li Y.-M. Advances in the study of berberine and its derivatives: A focus on anti-inflammatory and anti-tumor effects in the digestive system. Acta Pharmacol. Sin. 2016;38:157&#x2013;167. doi: 10.1038/aps.2016.125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aps.2016.125</ArticleId><ArticleId IdType="pmc">PMC5309756</ArticleId><ArticleId IdType="pubmed">27917872</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Li X., Zou D., Liu W., Yang J., Zhu N., Huo L., Wang M., Hong J., Wu P., et al. Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine. J. Clin. Endocrinol. Metab. 2008;93:2559&#x2013;2565. doi: 10.1210/jc.2007-2404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2007-2404</ArticleId><ArticleId IdType="pubmed">18397984</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing Y., Dong X., Hongli L., Yanhui L. Berberine promoted myocardial protection of postoperative patients through regulating myocardial autophagy. Biomed. Pharmacother. 2018;105:1050&#x2013;1053. doi: 10.1016/j.biopha.2018.06.088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.06.088</ArticleId><ArticleId IdType="pubmed">30021340</ArticleId></ArticleIdList></Reference><Reference><Citation>Cazzaniga M., Bonanni B. Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine? Anticancer. Res. 2018;38:4393&#x2013;4402. doi: 10.21873/anticanres.12741.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.12741</ArticleId><ArticleId IdType="pubmed">30061203</ArticleId></ArticleIdList></Reference><Reference><Citation>Imenshahidi M., Hosseinzadeh H. Berberis Vulgarisand Berberine: An Update Review. Phytotherapy Res. 2016;30:1745&#x2013;1764. doi: 10.1002/ptr.5693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.5693</ArticleId><ArticleId IdType="pubmed">27528198</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Z., Wang C., He W., Chen Y. Berberine Alleviates Amyloid-Beta Pathology in the Brain of APP/PS1 Transgenic Mice via Inhibiting &#x3b2;/&#x3b3;-Secretases Activity and Enhancing &#x3b1;-Secretases. Curr. Alzheimer Res. 2018;15:1045&#x2013;1052. doi: 10.2174/1567205015666180702105740.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205015666180702105740</ArticleId><ArticleId IdType="pubmed">29962345</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Zhao C., Cao G., Guo L., Zhang S., Liang Y., Qin C., Su P., Li H., Zhang W. Berberine modulates amyloid-&#x3b2; peptide generation by activating AMP-activated protein kinase. Neuropharmacology. 2017;125:408&#x2013;417. doi: 10.1016/j.neuropharm.2017.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2017.08.013</ArticleId><ArticleId IdType="pubmed">28822725</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.-F., Lee Y.-C., Lee K.-H., Lin H.-C., Chen C.-L., Shen C.-K.J., Huang C.-C. Therapeutic effect of berberine on TDP-43-related pathogenesis in FTLD and ALS. J. Biomed. Sci. 2016;23:72. doi: 10.1186/s12929-016-0290-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-016-0290-z</ArticleId><ArticleId IdType="pmc">PMC5073438</ArticleId><ArticleId IdType="pubmed">27769241</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang W., Wei W., Gaertig M.A., Li S., Li X.-J. Therapeutic Effect of Berberine on Huntington&#x2019;s Disease Transgenic Mouse Model. PLoS ONE. 2015;10:e0134142. doi: 10.1371/journal.pone.0134142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0134142</ArticleId><ArticleId IdType="pmc">PMC4520448</ArticleId><ArticleId IdType="pubmed">26225560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M., Cho K.-H., Shin M., Lee J.-M., Cho H.-S., Kim C.-J., Shin D.-H., Yang H.J. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson&#x2019;s disease. Int. J. Mol. Med. 2014;33:870&#x2013;878. doi: 10.3892/ijmm.2014.1656.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2014.1656</ArticleId><ArticleId IdType="pubmed">24535622</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan D., Liu L., Wu Z., Cao M. Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential. Curr. Neuropharmacol. 2019;17:563&#x2013;579. doi: 10.2174/1570159X16666180419141613.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X16666180419141613</ArticleId><ArticleId IdType="pmc">PMC6712296</ArticleId><ArticleId IdType="pubmed">29676231</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Z., Wang C., Yang W. Role of berberine in Alzheimer&#x2019;s disease. Neuropsychiatr. Dis. Treat. 2016;12:2509&#x2013;2520. doi: 10.2147/NDT.S114846.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S114846</ArticleId><ArticleId IdType="pmc">PMC5055107</ArticleId><ArticleId IdType="pubmed">27757035</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghani M., Shabani M., Tondar M. The Therapeutic Potential of Berberine against the Altered Intrinsic Properties of the CA1 Neurons Induced by A&#x3b2; Neurotoxicity. Eur. J. Pharmacol. 2015;758:82&#x2013;88. doi: 10.1016/j.ejphar.2015.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2015.03.016</ArticleId><ArticleId IdType="pubmed">25861937</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M., Jiang X., Liang Y., Liu Q., Chen S., Guo Y. Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of &#x3b2;-amyloid in APP/tau/PS1 mouse model of Alzheimer&#x2019;s disease. Exp. Gerontol. 2017;91:25&#x2013;33. doi: 10.1016/j.exger.2017.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2017.02.004</ArticleId><ArticleId IdType="pubmed">28223223</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Bian H., Guo L., Zhu H. Pharmacologic preconditioning with berberine attenuating ischemia-induced apoptosis and promoting autophagy in neuron. Am. J. Transl. Res. 2016;8:1197&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4846963</ArticleId><ArticleId IdType="pubmed">27158406</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu Y.-Y., Chen C.-S., Wu S.-N., Jong Y.-J., Lo Y.-C. Berberine activates Nrf2 nuclear translocation and protects against oxidative damage via a phosphatidylinositol 3-kinase/Akt-dependent mechanism in NSC34 motor neuron-like cells. Eur. J. Pharm. Sci. 2012;46:415&#x2013;425. doi: 10.1016/j.ejps.2012.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2012.03.004</ArticleId><ArticleId IdType="pubmed">22469516</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinozzi S., Colliva C., Camborata C., Roberti M., Ianni C., Neri F., Calvarese C., Lisotti A., Mazzella G., Roda A. Berberine and Its Metabolites: Relationship between Physicochemical Properties and Plasma Levels after Administration to Human Subjects. J. Nat. Prod. 2014;77:766&#x2013;772. doi: 10.1021/np400607k.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/np400607k</ArticleId><ArticleId IdType="pubmed">24593257</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo F., Nakamura N., Akao T., Hattori M. Pharmacokinetics of Berberine and Its Main Metabolites in Conventional and Pseudo Germ-Free Rats Determined by Liquid Chromatography/Ion Trap Mass Spectrometry. Drug Metab. Dispos. 2006;34:2064&#x2013;2072. doi: 10.1124/dmd.106.011361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.106.011361</ArticleId><ArticleId IdType="pubmed">16956957</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X.-S., Ma J.-Y., Feng R., Ma C., Chen W.-J., Sun Y.-P., Fu J., Huang M., He C.-Y., Shou J.-W., et al. Tissue Distribution of Berberine and Its Metabolites after Oral Administration in Rats. PLoS ONE. 2013;8:e77969. doi: 10.1371/journal.pone.0077969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0077969</ArticleId><ArticleId IdType="pmc">PMC3815028</ArticleId><ArticleId IdType="pubmed">24205048</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheir M., Wang Y., Hua L., Hu J., Li L., Lei F., Du L.-J. Acute toxicity of berberine and its correlation with the blood concentration in mice. Food Chem. Toxicol. 2010;48:1105&#x2013;1110. doi: 10.1016/j.fct.2010.01.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2010.01.033</ArticleId><ArticleId IdType="pubmed">20138204</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Hao H., Xie H.-G., Lai L., Wang Q., Liu C., Wang G. Extensive Intestinal First-Pass Elimination and Predominant Hepatic Distribution of Berberine Explain Its Low Plasma Levels in Rats. Drug Metab. Dispos. 2010;38:1779&#x2013;1784. doi: 10.1124/dmd.110.033936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.110.033936</ArticleId><ArticleId IdType="pubmed">20634337</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.-S., Zheng Y.-R., Zhang Y.-F., Long X.-Y. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia. 2016;109:274&#x2013;282. doi: 10.1016/j.fitote.2016.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fitote.2016.02.001</ArticleId><ArticleId IdType="pubmed">26851175</ArticleId></ArticleIdList></Reference><Reference><Citation>Waters M.L. Aromatic interactions in model systems. Curr. Opin. Chem. Biol. 2002;6:736&#x2013;741. doi: 10.1016/S1367-5931(02)00359-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1367-5931(02)00359-9</ArticleId><ArticleId IdType="pubmed">12470725</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley K.E., Hobza P. On the Importance and Origin of Aromatic Interactions in Chemistry and Biodisciplines. Accounts Chem. Res. 2012;46:927&#x2013;936. doi: 10.1021/ar300083h.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ar300083h</ArticleId><ArticleId IdType="pubmed">22872015</ArticleId></ArticleIdList></Reference><Reference><Citation>Akula S., Candido S., Libra M., Abrams S.L., Steelman L.S., Lertpiriyapong K., Ramazzotti G., Ratti S., Follo M.Y., Martelli A.M., et al. Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. Adv. Biol. Regul. 2019;73:100633. doi: 10.1016/j.jbior.2019.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbior.2019.04.003</ArticleId><ArticleId IdType="pubmed">31047842</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierpaoli E., Damiani E., Orlando F., Lucarini G., Bartozzi B., Lombardi P., Salvatore C., Geroni C., Donati A., Provinciali M. Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma. Carcinogenesis. 2015;36:1169&#x2013;1179. doi: 10.1093/carcin/bgv103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgv103</ArticleId><ArticleId IdType="pubmed">26168818</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrams S.L., Follo M.Y., Steelman L.S., Lertpiriyapong K., Cocco L., Ratti S., Martelli A.M., Candido S., Libra M., Murata R.M., et al. Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. Adv. Biol. Regul. 2019;71:172&#x2013;182. doi: 10.1016/j.jbior.2018.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbior.2018.10.003</ArticleId><ArticleId IdType="pubmed">30361003</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierpaoli E., Fiorillo G., Lombardi P., Salvatore C., Geroni C., Piacenza F., Provinciali M. Antitumor activity of NAX060: A novel semisynthetic berberine derivative in breast cancer cells. BioFactors. 2018;44:443&#x2013;452. doi: 10.1002/biof.1440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1440</ArticleId><ArticleId IdType="pubmed">30178609</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcelli M., Stenoien D.L., Szafran A.T., Simeoni S., Agoulnik I.U., Weigel N.L., Moran T., Mikic I., Price J.H., Mancini M.A. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J. Cell. Biochem. 2006;98:770&#x2013;788. doi: 10.1002/jcb.20593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.20593</ArticleId><ArticleId IdType="pubmed">16440331</ArticleId></ArticleIdList></Reference><Reference><Citation>Szafran A.T., Szwarc M., Marcelli M., Mancini M. Androgen Receptor Functional Analyses by High Throughput Imaging: Determination of Ligand, Cell Cycle, and Mutation-Specific Effects. PLoS ONE. 2008;3:e3605. doi: 10.1371/journal.pone.0003605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003605</ArticleId><ArticleId IdType="pmc">PMC2572143</ArticleId><ArticleId IdType="pubmed">18978937</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P., Crippa V., Giorgetti E., Boncoraglio A., Cristofani R., Carra S., Poletti A. Clearance of the mutant androgen receptor in motoneuronal models of spinal and bulbar muscular atrophy. Neurobiol. Aging. 2013;34:2585&#x2013;2603. doi: 10.1016/j.neurobiolaging.2013.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.05.026</ArticleId><ArticleId IdType="pmc">PMC3748343</ArticleId><ArticleId IdType="pubmed">23810450</ArticleId></ArticleIdList></Reference><Reference><Citation>Landles C., Sathasivam K., Weiss A., Woodman B., Moffitt H., Finkbeiner S., Sun B., Gafni J., Ellerby L.M., Trottier Y., et al. Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease. J. Biol. Chem. 2010;285:8808&#x2013;8823. doi: 10.1074/jbc.M109.075028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.075028</ArticleId><ArticleId IdType="pmc">PMC2838303</ArticleId><ArticleId IdType="pubmed">20086007</ArticleId></ArticleIdList></Reference><Reference><Citation>Neueder A., Landles C., Ghosh R., Howland D., Myers R., Faull R.L.M., Tabrizi S.J., Bates G. The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington&#x2019;s disease patients. Sci. Rep. 2017;7:1307. doi: 10.1038/s41598-017-01510-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-01510-z</ArticleId><ArticleId IdType="pmc">PMC5431000</ArticleId><ArticleId IdType="pubmed">28465506</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Cao B., Liu X., Fu X., Xiong Z., Chen L., Sartor O., Dong Y., Zhang H. Berberine suppresses androgen receptor signaling in prostate cancer. Mol. Cancer Ther. 2011;10:1346&#x2013;1356. doi: 10.1158/1535-7163.MCT-10-0985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-10-0985</ArticleId><ArticleId IdType="pmc">PMC3154574</ArticleId><ArticleId IdType="pubmed">21613449</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra H., Cordova M., Chen C.-S.J., Rajadhyaksha M. Confocal imaging-guided laser ablation of basal cell carcinomas: An ex vivo study. J. Investig. Dermatol. 2014;135:612&#x2013;615. doi: 10.1038/jid.2014.371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jid.2014.371</ArticleId><ArticleId IdType="pmc">PMC4289436</ArticleId><ArticleId IdType="pubmed">25178106</ArticleId></ArticleIdList></Reference><Reference><Citation>Waza M., Adachi H., Katsuno M., Minamiyama M., Tanaka F., Sobue G. Alleviating Neurodegeneration by an Anticancer Agent: An Hsp90 Inhibitor (17-AAG) Ann. N. Y. Acad. Sci. 2006;1086:21&#x2013;34. doi: 10.1196/annals.1377.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1377.012</ArticleId><ArticleId IdType="pubmed">17185503</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P., Simonini F., Crippa V., Bolzoni E., Onesto E., Cagnin M., Sau D., Ferri N., Poletti A. 17-AAG increases autophagic removal of mutant androgen receptor in spinal and bulbar muscular atrophy. Neurobiol. Dis. 2011;41:83&#x2013;95. doi: 10.1016/j.nbd.2010.08.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.08.023</ArticleId><ArticleId IdType="pubmed">20816782</ArticleId></ArticleIdList></Reference><Reference><Citation>Adachi H., Waza M., Tokui K., Katsuno M., Minamiyama M., Tanaka F., Doyu M., Sobue G. CHIP Overexpression Reduces Mutant Androgen Receptor Protein and Ameliorates Phenotypes of the Spinal and Bulbar Muscular Atrophy Transgenic Mouse Model. J. Neurosci. 2007;27:5115&#x2013;5126. doi: 10.1523/JNEUROSCI.1242-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1242-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672370</ArticleId><ArticleId IdType="pubmed">17494697</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt W.B., Gestwicki J.E., Osawa Y., Lieberman A.P. Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 2014;55:353&#x2013;371. doi: 10.1146/annurev-pharmtox-010814-124332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010814-124332</ArticleId><ArticleId IdType="pmc">PMC4372135</ArticleId><ArticleId IdType="pubmed">25292434</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas M., Harrell J.M., Morishima Y., Peng H.-M., Pratt W.B., Lieberman A.P. Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction. Hum. Mol. Genet. 2006;15:1876&#x2013;1883. doi: 10.1093/hmg/ddl110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddl110</ArticleId><ArticleId IdType="pubmed">16644868</ArticleId></ArticleIdList></Reference><Reference><Citation>Montie H.L., Cho M.S., Holder L., Liu Y., Tsvetkov A.S., Finkbeiner S., Merry D.E. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 2009;18:1937&#x2013;1950. doi: 10.1093/hmg/ddp115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp115</ArticleId><ArticleId IdType="pmc">PMC2678926</ArticleId><ArticleId IdType="pubmed">19279159</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedelsky N.B., Pennuto M., Smith R.B., Palazzolo I., Moore J., Nie Z., Neale G., Taylor J.P. Native Functions of the Androgen Receptor Are Essential to Pathogenesis in a Drosophila Model of Spinobulbar Muscular Atrophy. Neuron. 2010;67:936&#x2013;952. doi: 10.1016/j.neuron.2010.08.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.08.034</ArticleId><ArticleId IdType="pmc">PMC3514079</ArticleId><ArticleId IdType="pubmed">20869592</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeyama K.-I., Ito S., Yamamoto A., Tanimoto H., Furutani T., Kanuka H., Miura M., Tabata T., Kato S. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron. 2002;35:855&#x2013;864. doi: 10.1016/S0896-6273(02)00875-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00875-9</ArticleId><ArticleId IdType="pubmed">12372281</ArticleId></ArticleIdList></Reference><Reference><Citation>Walcott J.L., Merry D.E. Ligand Promotes Intranuclear Inclusions in a Novel Cell Model of Spinal and Bulbar Muscular Atrophy. J. Biol. Chem. 2002;277:50855&#x2013;50859. doi: 10.1074/jbc.M209466200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M209466200</ArticleId><ArticleId IdType="pubmed">12388541</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Miwa S., Kobayashi Y., Merry D.E., Yamamoto M., Tanaka F., Doyu M., Hashizum Y., Fischbeck K.H., Sobue G. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann. Neurol. 1998;44:249&#x2013;254. doi: 10.1002/ana.410440216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410440216</ArticleId><ArticleId IdType="pubmed">9708548</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodi S., Pennuto M. Neurotoxic effects of androgens in spinal and bulbar muscular atrophy. Front. Neuroendocr. 2011;32:416&#x2013;425. doi: 10.1016/j.yfrne.2011.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yfrne.2011.06.003</ArticleId><ArticleId IdType="pubmed">21745497</ArticleId></ArticleIdList></Reference><Reference><Citation>Thirupurasundari C.J., Padmini R., Devaraj S.N. Effect of berberine on the antioxidant status, ultrastructural modifications and protein bound carbohydrates in azoxymethane-induced colon cancer in rats. Chem. Interactions. 2009;177:190&#x2013;195. doi: 10.1016/j.cbi.2008.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2008.09.027</ArticleId><ArticleId IdType="pubmed">18951886</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong B., Li H., Singh A.B., Cao A., Liu J. Inhibition ofPCSK9Transcription by Berberine Involves Down-regulation of Hepatic HNF1&#x3b1; Protein Expression through the Ubiquitin-Proteasome Degradation Pathway. J. Biol. Chem. 2014;290:4047&#x2013;4058. doi: 10.1074/jbc.M114.597229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.597229</ArticleId><ArticleId IdType="pmc">PMC4326815</ArticleId><ArticleId IdType="pubmed">25540198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N., Wang X., Tan H.-Y., Li S., Tsang C.M., Tsao S.-W., Feng Y. Berberine Suppresses Cyclin D1 Expression through Proteasomal Degradation in Human Hepatoma Cells. Int. J. Mol. Sci. 2016;17:1899. doi: 10.3390/ijms17111899.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms17111899</ArticleId><ArticleId IdType="pmc">PMC5133898</ArticleId><ArticleId IdType="pubmed">27854312</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A., Liu Q., Li Q., Liu B., Yang Y., Zhang N. Berberine Reduces Pyruvate-driven Hepatic Glucose Production by Limiting Mitochondrial Import of Pyruvate through Mitochondrial Pyruvate Carrier 1. EBioMedicine. 2018;34:243&#x2013;255. doi: 10.1016/j.ebiom.2018.07.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.07.039</ArticleId><ArticleId IdType="pmc">PMC6117739</ArticleId><ArticleId IdType="pubmed">30093307</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz L.M.G., Tillhon M., Parks M., Dutto I., Prosperi E., Savio M., Arcamone A.G., Buzzetti F., Lombardi P., Scovassi A.I. Multiple Effects of Berberine Derivatives on Colon Cancer Cells. BioMed Res. Int. 2014;2014:924585. doi: 10.1155/2014/924585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/924585</ArticleId><ArticleId IdType="pmc">PMC4086420</ArticleId><ArticleId IdType="pubmed">25045712</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenoien D.L., Cummings C.J., Adams H.P., Mancini M.A., Patel K., DeMartino G.N., Marcelli M., Weigel N.L. Polyglutamine-Expanded Androgen Receptors Form Aggregates That Sequester Heat Shock Proteins, Proteasome Components and SRC-1, and Are Suppressed by the HDJ-2 Chaperone. Hum. Mol. Genet. 1999;8:731&#x2013;741. doi: 10.1093/hmg/8.5.731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/8.5.731</ArticleId><ArticleId IdType="pubmed">10196362</ArticleId></ArticleIdList></Reference><Reference><Citation>Cashman N.R., Durham H.D., Blusztajn J.K., Oda K., Tabira T., Shaw I.T., Dahrouge S., Antel J.P. Neuroblastoma &#xd7; spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev. Dyn. 1992;194:209&#x2013;221. doi: 10.1002/aja.1001940306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/aja.1001940306</ArticleId><ArticleId IdType="pubmed">1467557</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccioni F., Pinton P., Simeoni S., Pozzi P., Fascio U., Vismara G., Martini L., Rizzuto R., Poletti A. Androgen receptor with elongated polyglutamine tract forms aggregates that alter axonal trafficking and mitochondrial distribution in motoneuronal processes. FASEB J. 2002;16:1418&#x2013;1420. doi: 10.1096/fj.01-1035fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.01-1035fje</ArticleId><ArticleId IdType="pubmed">12205033</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi P., Bendotti C., Simeoni S., Piccioni F., Guerini V., Marron T.U., Martini L., Poletti A. Androgen 5-alpha-reductase type 2 is highly expressed and active in rat spinal cord motor neurones. J. Neuroendocr. 2003;15:882&#x2013;887. doi: 10.1046/j.1365-2826.2003.01074.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2826.2003.01074.x</ArticleId><ArticleId IdType="pubmed">12899683</ArticleId></ArticleIdList></Reference><Reference><Citation>Crippa V., Sau D., Rusmini P., Boncoraglio A., Onesto E., Bolzoni E., Galbiati M., Fontana E., Marino M., Carra S., et al. The small heat shock protein B8 (HspB8) promotes autophagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS) Hum. Mol. Genet. 2010;19:3440&#x2013;3456. doi: 10.1093/hmg/ddq257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq257</ArticleId><ArticleId IdType="pubmed">20570967</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>